백서 신경병증통증 모델에서 유도된 ERK 1/2와 CREB 신호 단백질에 대한 Ketamine의 억제효과 = Low dose ketamine reduces the induction of ERK1/2 and CREB signaling protein in a neuropathic pain model of rats

다국어 초록 (Multilingual Abstract)

Background: In addition to causing the loss of voluntary sensory and motor function, spinal cord injury (SCI) often creates a state of central neuropathic pain. Rats given SCI display increases in the activated form of transcription factors ERK 1/2 MAPK and CREB in the spinal cord, which correspond to allodynia in a model of neuropathic pain. This study was conducted to determine if low dose ketamine had an effect on the activation of ERK 1/2 and CREB in the development of neuropathic pain.
Methods: This study was conducted to evaluate ERK 1/2 and CREB protein in a sham operated (control) group, neuropathic pain and normal saline (NP ＋ NS) group and neuropathic pain and ketamine (NP ＋ Keta) group. To accomplish this, male Sprague-Dawley rats were anesthetized and then subjected to L5-L6 spinal nerve ligation (SNL, neuropathic rats). The total amounts of ERK 1/2 and CREB protein were then assessed by western blot analysis. In addition, changes in the amounts of ERK 1/2 and CREB mRNA were evaluated by RT-PCR.
Results: There was a significant increase in the amount of ERK 1/2 and CREB in the NP ＋ NS group when compared with the sham group. However, the amount of ERK 1/2 and CREB protein induced due to SNL were significantly reduced by continuous infusion with ketamine in the NP ＋ Keta group.
Conclusions: The results of this study revealed a positive linkage between NMDA receptors and the ERK-CREB signaling pathway. Therefore, NMDA receptors could be the target of future therapeutic approaches. Additionally, the results of the present study provide additional evidence that low dose ketamine effectively prevents and treats central neuropathic pain following SNL.

다국어 초록 (Multilingual Abstract)

Background: In addition to causing the loss of voluntary sensory and motor function, spinal cord injury (SCI) often creates a state of central neuropathic pain. Rats given SCI display increases in the activated form of transcription factors ERK 1/2 MAPK and CREB in the spinal cord, which correspond to allodynia in a model of neuropathic pain. This study was conducted to determine if low dose ketamine had an effect on the activation of ERK 1/2 and CREB in the development of neuropathic pain.
Methods: This study was conducted to evaluate ERK 1/2 and CREB protein in a sham operated (control) group, neuropathic pain and normal saline (NP ＋ NS) group and neuropathic pain and ketamine (NP ＋ Keta) group. To accomplish this, male Sprague-Dawley rats were anesthetized and then subjected to L5-L6 spinal nerve ligation (SNL, neuropathic rats). The total amounts of ERK 1/2 and CREB protein were then assessed by western blot analysis. In addition, changes in the amounts of ERK 1/2 and CREB mRNA were evaluated by RT-PCR.
Results: There was a significant increase in the amount of ERK 1/2 and CREB in the NP ＋ NS group when compared with the sham group. However, the amount of ERK 1/2 and CREB protein induced due to SNL were significantly reduced by continuous infusion with ketamine in the NP ＋ Keta group.
Conclusions: The results of this study revealed a positive linkage between NMDA receptors and the ERK-CREB signaling pathway. Therefore, NMDA receptors could be the target of future therapeutic approaches. Additionally, the results of the present study provide additional evidence that low dose ketamine effectively prevents and treats central neuropathic pain following SNL.

참고문헌 (Reference)

1 이현정, "흰 쥐의 신경병증성 통증 모델에서 Gabapentin과 Milnacipran의 병용 효과" 대한통증학회 20 (20): 2-2, 2007

2 심범, "신경병증성 통증모델 쥐에서 피부통각수용체의 민감화" 대한통증학회 15 (15): 32-42, 2002

3 Xu JT, "activation in uninjured primary afferent neurons and in spinal microglia contributes to the development of neuropathic pain induced by selective motor fiber injury" 204 : 355-365, 2007

4 Visser E, "The role of ketamine in pain management" 60 : 341-348, 2006

5 Ultenius C, "Spinal NMDA receptor phosphorylation correlates with the presence of neuropathic signs following peripheral nerve injury in the rat" 399 : 85-90, 2006

6 Labombarda F, "Neuropathic pain and temporal expression of preprodynorphin, protein kinase C and N-methyl-d-aspartate receptor subunits after spinal cord injury" 447 : 115-119, 2008

7 Houghton AK, "Mrz 2/579, a fast kinetic NMDA channel blocker, reduces the development of morphine tolerance in awake rats" 91 : 201-207, 2001

8 Nakanishi S, "Molecular diversity of glutamate receptors and their physiological functions" 71 : 71-80, 1994

9 Baron R, "Mechanisms of disease: neuropathic pain--a clinical perspective" 2 : 95-106, 2006

10 Willis WD, "Long-term potentiation in spinothalamic neurons" 40 : 202-214, 2002

11 Hevers W, "Ketamine, but not phencyclidine, selectively modulates cerebellar GABA (A) receptors containing alpha6 and delta subunits" 28 : 5383-5393, 2008

12 Warncke T, "Ketamine, an NMDA receptor antagonist, suppresses spatial and temporal properties of burn-induced secondary hyperalgesia in man: a double-blind, crossover comparison with morphine and placebo" 72 : 99-106, 1997

13 Schnoebel R, "Ketamine impairs excitability in superficial dorsal horn neurones by blocking sodium and voltage-gated potassium currents" 146 : 826-833, 2005

14 Durrani Z, "Ketamine for intravenous regional anesthesia" 68 : 328-333, 1989

15 Mao L, "Interactions between ionotropic and metabotropic glutamate receptors regulate cAMP response element-binding protein phosphorylation in cultured striatal neurons" 115 : 395-402, 2002

16 Crown ED, "Increases in the activated forms of ERK 1/2, p38 MAPK, and CREB are correlated with the expression of at-level mechanical allodynia following spinal cord injury" 199 : 397-407, 2006

17 Ma W, "Increased phosphorylation of cyclic AMP response element-binding protein (CREB) in the superficial dorsal horn neurons following partial sciatic nerve ligation" 93 : 295-301, 2001

18 Vanhoutte P, "Glutamate induces phosphorylation of Elk-1 and CREB, along with c-fos activation, via an extracellular signal-regulated kinase-dependent pathway in brain slices" 19 : 136-146, 1999

19 Haley JE, "Evidence for spinal N-methyl-D-aspartate receptor involvement in prolonged chemical nociception in the rat" 518 : 218-226, 1990

20 Gao X, "Enhancement of NMDA receptor phosphorylation of the spinal dorsal horn and nucleus gracilis neurons in neuropathic rats" 116 : 62-72, 2005

21 Eide K, "Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia" 61 : 221-228, 1995

22 Christensen MD, "Chronic central pain after spinal cord injury" 14 : 517-537, 1997

23 Yoshii A, "BDNF induces transport of PSD-95 to dendrites through PI3K-AKT signaling after NMDA receptor activation" 10 : 702-711, 2007

24 Kim SH, "An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat" 50 : 355-363, 1992

25 Woolf CJ, "American College of Physicians, American Physiological Society: Pain: moving from symptom control toward mechanism-specific pharmacologic management" 140 : 441-451, 2004

26 Sato J, "Adrenergic excitation of cutaneous pain receptors induced by peripheral nerve injury" 251 : 1608-1610, 1991

27 Lee HT, "Adenosine attenuates oxidant injury in human proximal tubular cells via A (1) and A (2a) adenosine receptors" 282 : 844-852, 2002

28 Garry EM, "Activation of p38 and p42/44 MAP kinase in neuropathic pain: involvement of VPAC2 and NK2 receptors and mediation by spinal glia" 30 : 523-537, 2005

29 Song XS, "Activation of ERK/CREB pathway in spinal cord contributes to chronic constrictive injury-induced neuropathic pain in rats" 26 : 789-798, 2005

30 Faden AI, "A potential role for excitotoxins in the pathophysiology of spinal cord injury" 23 : 623-626, 1988